Comparative Pharmacology
Head-to-head clinical analysis: KALEXATE versus LEXAPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KALEXATE versus LEXAPRO.
KALEXATE vs LEXAPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.
10 mg orally once daily.
10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.
None Documented
None Documented
12-15 hours; prolonged in renal impairment (up to 30 hours in severe cases)
27-32 hours (mean ~30 h); steady state reached in ~1 week; linear kinetics at therapeutic doses.
Primarily renal (75-80% as unchanged drug); biliary/fecal (15-20%)
Primarily renal (approx. 80% as metabolites, 8% as unchanged drug); biliary/fecal elimination accounts for ~15%.
Category C
Category C
SSRI Antidepressant
SSRI Antidepressant